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ABSTRACT
Introduction: Febrile neutropenia (FN) is a
serious and frequent complication of cytotoxic
chemotherapy. Biosimilar filgrastim
(NivestimTM, Hospira Inc, A Pfizer Company,
Lake Forest, IL, USA) is a granulocyte-colony
stimulating factor licensed for the treatment of
neutropenia and FN induced by
myelosuppressive chemotherapy. The primary
goal of this VENICE study (ClinicalTrials.gov
identifier, NCT01627990) was to observe the
tolerability, safety and efficacy of biosimilar
filgrastim in patients receiving cancer
chemotherapy.
Methods: This was a prospective, multicenter,
non-interventional, longitudinal study.
Consenting adult patients with solid tumors or
hematologic malignancies for whom cytotoxic
chemotherapy and treatment with biosimilar
filgrastim was planned were enrolled.
Results: Among the enrolled patients (N = 386),
81% were female, with a median age (range) of 61
(22–92) years, with 39% [65 years old. Most
patients (n = 338; 88%) had solid tumors and the
remainder (n = 49; 13%) had hematological
malignancies. The majority of the patients
(64%) received biosimilar filgrastim as primary
prophylaxis and 36% as secondary prophylaxis.
At the follow-up visits, for the majority of
patients (95.6%) there had been no change in
chemotherapy dose due to FN. For two patients
(0.5%) the chemotherapy was discontinued due
to FN and for four patients (1.0%) the
chemotherapy dose was reduced due to FN. For
the majority of patients (96.9%) the
chemotherapy cycle following the first
biosimilar filgrastim treatment was not delayed
due to FN. For 3 patients (0.8%), the
chemotherapy was delayed following the first
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biosimilar filgrastim treatment. Less than
one-third (29.8%) of the patients
experienced C1 adverse event that was at least
potentially related to biosimilar filgrastim
treatment.
Conclusions: Biosimilar filgrastim was effective
and well-tolerated in both the primary and
secondary prophylactic setting in patients
undergoing chemotherapy for solid tumors
and hematological malignancies.
Trial Registration: ClinicalTrials.gov identifier,
NCT01627990.
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INTRODUCTION
Chemotherapy-induced neutropenia (CIN) is a
common and serious complication of
myelosuppressive chemotherapy [1].
Neutropenia is associated with life-threatening
infections and may delay the chemotherapy
schedule, having a negative impact on early and
long-term outcomes [2]. It is associated with
significant morbidity and mortality, and may
increase the overall cost of providing cancer
therapy [3]. The results of three large-scale
studies demonstrated that primary prophylaxis
with a granulocyte-colony stimulating factor
(G-CSF) significantly reduces the incidence of
febrile neutropenia (FN) resulting from
cytotoxic chemotherapy [4–6]. Thus, G-CSF
products reduce the risk of infectious
complications and with it, the consequent loss
of therapeutic options, which may result from
neutropenia [7]. The use of a G-CSF plus
antibiotics may reduce hospitalization time
and improve the ability to achieve neutrophil
recovery in individuals with
chemotherapy-induced FN [8].
Several G-CSF biosimilar filgrastim products
[Ratiograstim (Ratiopharm, Ulm, Germany)
Tevagrastim (Teva, Petah Tikva, Israel),
Biograstim (CT Arzneimittel, Ulm, Germany)
Zarzio (Sandoz, Basel, Switzerland) Nivestim
(Hospira Inc, A Pfizer Company, Lake Forest, IL,
USA)] [9] to the reference product Neupogen
(Amgen, Thousand Oaks, USA) have been
approved in Europe [10]. All these products are
manufactured in facilities with state-of-the-art
technology and have passed the regulatory
requirements for approval, mainly phase I and
phase III trials, with the consequent
pharmacodynamic/pharmacokinetic (PD/PK)
evaluations and studies on efficacy and safety;
however, there are still some unresolved
questions regarding their long-term evaluation,
in particular, the limited real-world experience at
the time of approval of these products in terms of
efficacy, safety and immunogenicity.
Biosimilar filgrastim (Nivestim) is a
175-amino acid protein recombinant
methionyl human G-CSF, with a molecular
weight of 18,800 Da, that is produced in
Escherichia coli [11]. The active substance is
non-glycosylated protein, containing an
N-terminal methionyl extension. It stimulates
the proliferation, differentiation and activation
of late progenitor cells of the granulocyte
lineage and enhances the activity of mature
neutrophils.
Since the use of biosimilar filgrastim has not
yet been sufficiently documented in the context
of day-to-day medical practice, the goal of the
VENICE study, (i.e., Compatibility of Nivestim
with Cytotoxic Chemotherapy in the Treatment
of Malignant Diseases) (ClinicalTrials.gov
identifier, NCT01627990) was to assess the
tolerability, safety and efficacy of prophylactic
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biosimilar filgrastim to reduce the duration of
neutropenia and the incidence of FN in patients
receiving cytotoxic cancer chemotherapy [12].
The VENICE study was a multicenter,
prospective, longitudinal, observational study
designed to evaluate the use of biosimilar
filgrastim in ‘real-world’ clinical practice.
METHODS
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was not required from
patients as this was a non-interventional
observational trial.
Patient Population
The study enrolled children and adults of either
gender with solid or malignant hematological
tumors who were scheduled to undergo
prophylactic treatment with biosimilar
filgrastim (Nivestim) to shorten the duration
of a neutropenia, or to prevent the occurrence
of chemotherapy-induced FN. Reasons for
exclusion from the study included chronic
myeloid leukemia or myelodysplastic
syndrome, hypersensitivity to any component
of the biosimilar filgrastim product, not
undergoing chemotherapy, or being treated
curatively with G-CSF.
Primary Outcome Measures
The primary objective was to assess the
tolerability, safety and efficacy of prophylactic
treatment using biosimilar filgrastim in patients
receiving cytotoxic chemotherapy for cancer,
with an emphasis on patients undergoing
in-patient treatment.
Secondary Outcome Measures
The secondary objectives were to describe the
characteristics of patients being treated with
biosimilar filgrastim; the treatment modalities
using biosimilar filgrastim; and the
characteristics of participating physicians and
their prescribing practices with regard to G-CSF.
Subgroups
Patients were stratified according to age
(18–65 years old and[65 years old) and tumor
type (hematological vs. solid tumors). Other
parameters used for stratification analysis
included treatment site, infections (type,
affected area and causative organism), route of
administration (subcutaneous vs. intravenous)
and adverse events (AEs) (seriousness, severity,
and outcome).
Data Collection and Statistical Analysis
Patient data were gathered during the initial
enrollment visit and two subsequent follow-up
visits. AEs occurring during the study were
recorded regardless of causality. The
intent-to-treat (ITT) population consisted of all
patients enrolled in the study. The safety (SAF)
population included all patients who had at
least one follow-up visit or a documented AE.
The efficacy analysis set (probability
proportionate to size [PPS]) included patients
from the safety analysis set who fulfilled all the
inclusion/exclusion criteria and whose baseline
absolute neutrophil count (ANC) and one other
ANC value had been documented during
therapy or shortly afterwards.
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Reported data were analyzed descriptively.
Descriptive p values and confidence intervals
were calculated for the parameter of major
interest. For hospitalizations due to FN or
infections, all incidents occurring outside the
study duration were disregarded. Multiple
documentations of patient hospitalizations
occurring on the same date were regarded as
one single hospitalization. The incidence of
hospitalizations due to FN or infections are
presented as the absolute number of events, the
event rate per patient, the event rate per
patient-years, the absolute incidence, the
incidence rate per patient and the incidence
rate per patient-years. As each patient could
have been hospitalized more than once, a
multivariate logistic regression model was used
to investigate the influence of selected risk
factors on hospitalization. The risk factors of
interest were age (B65 years of age,[65 years of
age), tumor type (hematological or solid
tumor), and number of prior chemotherapy
regimens (B1, C2).
Adverse Events
AEs occurring before the screening visit were
disregarded. Other AEs were coded according to
Medical Dictionary for Regulatory Activities
(MedDRA) System Organ Class (SOC) and the
Preferred Term (PT). These were tabulated in
terms of numbers of patients with C1 AE,
percent with respect to the analyzed
population and the number of AEs. The
duration of AEs was analyzed using summary
statistics.
Sample Size Estimation
A precision of ±3 percent was planned,
assuming a probability of 20% for the
occurrence of hospitalization due to FN or
infection for each patient recruited during the
observation period. Assuming a confidence
level of 5%, a sample of 700 eligible patients
was planned to fulfill requirements for power.
RESULTS
Forty-eight study sites participated in the study,
each contributing 2–60 patients per site. The
ITT population included 386 adult patients
undergoing cytotoxic chemotherapy who were
prescribed biosimilar filgrastim to reduce the
duration of neutropenia and to reduce the
incidence of chemotherapy-induced FN. The
SAF population included 382 patients (99.0%)
and the PPS population included 185 patients
from the SAF (48.4%). Data for most patients
(84.4%) was available for all three study visits
and the median duration of observation was
64 days.
Demographic and Baseline Characteristics
Most study participants (81%) were female,
with a median age (range) of 61 (22–92) years
and 39% of the patients age were[65 years old,
having solid tumors (n = 338, 88%) or
hematological malignancies (n = 49, 13%).
One patient had both a solid tumor and a
hematological malignancy, but was counted in
the solid tumor group. Other demographic and
baseline clinical characteristics are summarized
in Table 1.
Medical History
At baseline, 46.1% of patients reported at least 1
prior diagnosis, 30.3% reported at least 2 prior
diagnoses and 18.4% reported at least 3 other
prior diagnoses. The number of prior diagnoses
was similar for all tumor types, with the most
frequently reported cardiovascular disease
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(26.9%), chronic obstructive pulmonary
disease, renal and liver failure reported (for
each, \5%), FN (2.6%), recurrent infections
(3.9%) and human immunodeficiency virus
(HIV) infection (0.5%) (Table 2).
Approximately half of enrolled patients
(42.5%) had received prior chemotherapy
(Table 3), but only 23.3% had received a
single prior regimen. Among the patients for
whom this information was available
(n = 158), 4.4% reported an episode of FN
after the most recent chemotherapy and
36.5% of the patients had no FN history after
chemotherapy. Overall, 19.4% of patients had
undergone prior radiotherapy, with a higher
rate among patients with other tumors
(33.3%).
Although hypotension, dermatitis,
mucositis, sepsis and erysipelas are risk factors
associated with FN, very few patients reported
these conditions at baseline. The most frequent
was mucositis (12.7%), followed by
hypotension (1.8%), dermatitis (0.8%) and
erysipelas (0.3%).










Male 24 (50.0) 1 (0.4) 50 (47.6) 75 (19.4)
Female 24 (50.0) 232 (99.6) 55 (52.4) 311 (80.6)
Median age (min, max),
years
68.0 (22.0, 80.0) 58.0 (23.0, 82.0) 68.0 (40.0, 92.0) 61.0 (22.0, 92.0)
Age categories, n (%)
18–65 19 (39.6) 173 (74.2) 45 (42.9) 237 (61.4)
[65 29 (60.4) 60 (25.8) 60 (57.1) 149 (38.6)
Median height (min, max),
cm (n)
48 232 102 382
171.0 (152.0, 192.0) 165.0 (150.0, 186.0) 169.5 (140.0, 194.0) 166.0 (140.0, 194.0)
Median body weight
(min, max), kg (n)
45 229 102 376
70.0 (41.0, 123.0) 71.0 (45.0, 119.0) 71.0 (43.0, 159.0) 71.0 (41.0, 159.0)
Median systolic BP
(min, max), mmHg (n)
27 176 67 270
120.0 (100.0, 160.0) 130.0 (99.0, 176.0) 129.0 (105.0, 170.0) 130.0 (99.0, 176.0)
Median diastolic BP
(min, max), mmHg (n)
27 175 67 269
80.0 (50.0, 90.0) 80.0 (50.0, 115.0) 75.0 (60.0, 99.0) 80.0 (50.0, 115.0)
Median body temperature
(min, max), C (n)
14 95 47 156
36.2 (35.2, 37.7) 36.5 (35.5, 38.5) 36.5 (35.0, 37.3) 36.5 (35.0, 38.5)
Patient 054-002 had a solid tumor as well as a hematological malignancy but was counted in the stratiﬁed analyses under
solid tumors
BP blood pressure, CD34 hematopoietic progenitor cell antigen CD34
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Tumor Entities
Forty-nine patients (12.7%) had a
hematological malignancy, including
Hodgkin’s lymphoma (n = 5, 1.3%),
non-Hodgkin’s lymphoma (n = 22; 5.7%),
monoclonal gammopathy (multiple myeloma
or Kahler disease; n = 9, 2.3%), chronic
lymphocytic leukemia (n = 9, 2.3%) or other
hematological malignancies (n = 4, 1.0%). The
median duration of disease at baseline was
3.0 years (range 1.0–18.0 years). Only three
patients (6.1%) had undergone autologous
stem cell transplantation. The disease
classification used for the hematological
malignancies was not consistent across
patients; however, the results indicate that
patients were distributed from early to late
staging groups. Most patients (87.6%) had
solid tumors and their median duration of
disease at baseline was 2.0 years (range,
1.0–52.0 years). Breast cancer was the largest
group among solid tumor patients (68.9%).
Other tumor types are summarized in Table 4.
Based on the TNM classification system, the
majority of solid tumors were small, low-grade
cancers with no metastasis, although they
ranged from Stage I to Stage IV.
Chemotherapy
The goal of chemotherapy for all patients at
enrollment was adjuvant (49%) or curative
(31.9%) (Table 5); with treatment being
predominantly curative among patients with
hematological malignancies (64.6%), but
predominantly adjuvant among patients with
breast cancer (63.1%). Among those with other
solid tumors, the goal was adjuvant (31.4%) or
curative therapy (29.5%).
For most patients, the planned
chemotherapy was first line treatment (63.5%)
and was similar across the tumor subgroups
Table 2 Medical history by tumor type (all-patient set)








Febrile neutropenia, n (%) 2 (4.2) 6 (2.6) 2 (1.9) 10 (2.6)
Recurrent infections, n (%) 3 (6.3) 8 (3.4) 4 (3.8) 15 (3.9)
HIV infection, n (%) 1 (2.1) 1 (0.4) 0 2 (0.5)
COPD, n (%) 2 (4.2) 3 (1.3) 10 (9.5) 15 (3.9)
Cardiovascular diseases, n (%) 12 (25.0) 54 (23.2) 38 (36.2) 104 (26.9)
Renal failure, n (%) 2 (4.2) 2 (0.9) 5 (4.8) 9 (2.3)
Liver failure, n (%) 0 2 (0.9) 0 2 (0.5)
Other or at least one other diagnosis, n (%) 24 (50.0) 97 (41.6) 57 (54.3) 178 (46.1)
At least two other diagnoses, n (%) 14 (29.2) 63 (27.0) 40 (38.1) 117 (30.3)
At least three other diagnoses, n (%) 7 (14.6) 42 (18.0) 22 (21.0) 71 (18.4)
Patient 054-002 had a solid tumor as well as a hematological malignancy but was counted in the stratiﬁed analyses under
solid tumors
HIV human immunodeﬁciency virus, COPD chronic obstructive pulmonary disease
a Prior diagnosis was not obtained in some cases
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(Table 5). For most, the treatment cycle
duration was 21 days (66.8%) and was planned
for six cycles (46.9%). At enrollment, most
patients were beginning their chemotherapy
(31.6%) or had already received one cycle
(29.8%). Most patients (65.3%) did not have
G-CSF prescribed during the first cycle (Table 6).
The most common chemotherapeutic agents
received by patients with hematological
malignancies were cyclophosphamide (66.7%),
rituximab (58.3%), doxorubicin (39.6%) and
vincristine (39.6%) (Table 7). Patients with
breast cancer most frequently received
cyclophosphamide (72.5%), epirubicin
(59.7%), docetaxel (37.8%), 5-fluorouracil
(30.5%) and paclitaxel (26.6%). Patients with
other solid tumors most frequently received
carboplatin (35.2%), 5-fluorouracil (24.8%) and
paclitaxel (21.0%).
Most patients with solid tumors (88.0% of
breast cancer, 88.6% of other solid tumors) did
not receive antibiotic prophylaxis; however,
58.3% of patients with hematological
malignancies were prophylactically treated
with antibiotics. Most (96.6%) did not receive
adjuvant radiotherapy.
During follow-up visits, for the majority of
patients (95.6%) there had been no change in
chemotherapy dose due to FN. For two patients
(0.5%) the chemotherapy was discontinued due
to FN and for four patients (1.0%) the
chemotherapy dose was reduced due to FN.
For the majority of patients (96.9%) the
chemotherapy cycle following the first
biosimilar filgrastim treatment was not
delayed due to FN. For three patients (0.8%),
the chemotherapy was delayed following the
first biosimilar filgrastim treatment.
Initial antibiotic prophylaxis was
administered to 12.7% of patients with
hematologic malignancies (n = 20, 41.7%) and
solid tumors (n = 29, 8.6%). Most did not
receive initial antibiotic prophylaxis.










Prior chemotherapy, n (%) 32 (66.7) 70 (30.0) 62 (59.0) 164 (42.5)
Number of prior chemotherapy
regimens, n (%)
0 3 (6.3) 2 (0.9) 1 (1.0) 6 (1.6)
1 14 (29.2) 43 (18.5) 33 (31.4) 90 (23.3)
2 4 (8.3) 6 (2.6) 12 (11.4) 22 (5.7)
3 4 (8.3) 7 (3.0) 8 (7.6) 19 (4.9)
4 2 (4.2) 3 (1.3) 1 (1.0) 6 (1.6)
5 1 (2.1) 1 (0.4) 1 (1.0) 3 (0.8)
6 0 3 (1.3) 2 (1.9) 5 (1.3)
8 1 (2.1) 2 (0.9) 0 3 (0.8)
9 1 (2.1) 1 (0.4) 0 2 (0.5)
60 0 0 1 (1.0) 1 (0.3)
Not recorded 18 165 46 229
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Only seven patients (1.8%) had
chemotherapy that was accompanied by
radiotherapy.
Weight, Vital Signs, Hospitalizations
Little change was observed in the median weight
and vital signs across tumor types during the
course of the study. No changes in weight or
vital signs were observed when evaluated by age
subgroup. Twenty-four patients had C1
hospitalizations due to general physical health
deterioration (n = 6), back pain, spinal pain,
device-related infection, diarrhea, leukopenia,
spinal pain and vomiting (for each, n = 2). The
median duration of hospitalization for patients
with hematological malignancies was 8 days
(n = 11; range 5–40 days) vs. 16.5 days (n = 38,
range 2–33 days) for patients with solid tumors.
Two hospitalizations due to FN or infections
were reported for patients with hematological
malignancies vs. seven for patients with solid
tumors.
The hospitalization rate for FN or infections
was 4.3% for the hematological malignancy
group and 2.1% for the solid tumor group. The
number of hospitalizations due to FN or
infections per patient-year was 0.2 for the
hematological malignancy group, 0.1 for the
breast cancer group and 0.1 for the other solid
tumor group. When number of hospitalizations
due to FN or infections was stratified by age,
patients B65 years old had more hospitalizations
(seven vs. two) and a higher rate of
hospitalizations (3.0 vs. 1.4 per 100 patients). In
the B65-year-old group, 2.5% were hospitalized
during the study vs. 1.4% in the [65-year-old
group. Logistic regression confirmed that older
patients had a lower risk of hospitalization due to
FN or infection [odds ratio (OR) 0.56, 95%
confidence interval (CI) 0.11–2.85]; however,
this difference was not statistically significant.
Similarly, the risk of hospitalization due to FN or
infection was not associated with the number of
prior cycles of chemotherapy at baseline (OR
1.07, 95% CI 0.25–4.55) or tumor type (OR 0.85,
95% CI 0.10–7.29).
Hematologic Laboratory Values
Median hemoglobin and thrombocyte values in
all tumor subgroups remained relatively
Table 4 Solid tumor types (all-patients set), N = 338
Location
Lung, n (%)
Small cell lung cancer 19 (5.6)



















Other, n (%) 7 (2.1)
a Two cases of esophageal cancer were placed in different
body locations
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stable throughout the study from enrollment to
last chemotherapy cycle, while median
leukocyte values showed a slight increase. For
patients with hematological malignancies, the
median leukocyte value at first visit was
3.2 9 109/L, increasing to 4.1 9 109/L before
the last chemotherapy cycle (Table 8). For
patients with breast cancer, the median
leukocyte value was 4.3 9 109/L, increasing to
5.3 9 109/L, while the median leukocyte value












Goal of chemotherapy Adjuvant 9 (18.8) 147 (63.1) 33 (31.4) 189 (49.0)
Curative 31 (64.6) 61 (26.2) 31 (29.5) 123 (31.9)
Line of treatment 1 30 (62.5) 151 (64.8) 64 (61.0) 245 (63.5)
2 5 (10.4) 8 (3.4) 23 (21.9) 36 (9.3)
3 4 (8.3) 2 (0.9) 7 (6.7) 13 (3.4)
4? 6 (12.5) 7 (3.0) 4 (3.8) 17 (4.4)
Duration of cycles 14 Days 5 (10.4) 15 (6.4) 17 (16.2) 37 (9.6)
21 Days 24 (50.0) 175 (75.1) 59 (56.2) 258 (66.8)
28 Days 12 (25.0) 12 (5.2) 15 (14.3) 39 (10.1)
Other 3 (6.3) 27 (11.6) 11 (10.5) 41 (10.6)
Number of originally
planned cycles
0 0 1 (0.4) 0 1 (0.3)
1 2 (4.2) 0 1 (1.0) 3 (0.8)
2 2 (4.2) 1 (0.4) 3 (2.9) 6 (1.6)
3 2 (4.2) 13 (5.6) 6 (5.7) 21 (5.4)
4 4 (8.3) 42 (18.0) 17 (16.2) 63 (16.3)
5 1 (2.1) 0 3 (2.9) 4 (1.0)
6 22 (45.8) 112 (48.1) 47 (44.8) 181 (46.9)
7 0 2 (0.9) 0 2 (0.5)
8 6 (12.5) 14 (6.0) 0 20 (5.2)
9 1 (2.1) 2 (0.9) 0 3 (0.8)
10 0 1 (0.4) 0 1 (0.3)
12 0 3 (1.3) 4 (3.8) 7 (1.8)
13 0 0 1 (1.0) 1 (0.3)
16 0 14 (6.0) 0 14 (3.6)
17 0 1 (0.4) 0 (0.0) 1 (0.3)
18 0 15 (6.4) 1 (1.0) 16 (4.1)
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for other solid tumors increased from 2.9 9 109/
L to 5.1 9 109/L. Similarly, median neutrophil
values increased from baseline to last
chemotherapy cycle. For patients with
hematological malignancies, the median
neutrophil value increased from 1.4 9 109/L to
2.6 9 109/L. For patients with breast cancer, the
median neutrophil value of 1.6 9 109/L
increased to 3.1 9 109/L while the median
neutrophil value for other solid malignancies
increased from 1.1 9 109/L to 3.0 9 109/L. For
patients with hematological malignancies, the
median C-reactive protein (CRP) value
increased from 4.5 to 5.0 mg/L. For patients
with breast cancer, the median CRP value
increased from 5.2 to 5.6 mg/L and the
median CRP value for patients with other solid
tumors increased from 9.7 to 10.6 mg/L.
Infections
Among patients for whom infection data were
collected, 11.3% had an infection at first visit,
13.1% had an infection at the follow-up visit
and 14.9% of the patients had an infection at a
later chemotherapy cycle. Bacterial and viral
infections were most frequently reported.
Adverse Events
In the course of the study, 29.8% of patients
experienced C1 AE that was at least potentially
related to biosimilar filgrastim treatment
(Table 9). The treatment related AEs reported
most frequently were musculoskeletal and
connective tissue disorders (12.3%) with the













Number of completed cycles 0 9 (18.8) 85 (36.5) 28 (26.7) 122 (31.6)
1 18 (37.5) 59 (25.3) 38 (36.2) 115 (29.8)
2 6 (12.5) 22 (9.4) 12 (11.4) 40 (10.4)
3 3 (6.3) 33 (14.2) 12 (11.4) 48 (12.4)
4 7 (14.6) 24 (10.3) 4 (3.8) 35 (9.1)
5 2 (4.2) 4 (1.7) 0 6 (1.6)
a Prior treatment was not obtained in some cases









Primary prophylaxis 22 (46.8) 160 (68.7) 61 (59.8) 243 (63.6)
Secondary prophylaxis 25 (53.2) 73 (31.3) 40 (39.2) 138 (36.1)
Not recorded 0 0 1 1
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Table 7 Chemotherapies, all-patients set









Antimetabolites Methotrexate 1 (2.1) 0 0 1 (0.3)
Gemcitabine 0 4 (1.7) 5 (4.8) 9 (2.3)
Fludarabin 7 (14.6) 0 1 (1.0) 8 (2.1)
Cytarabin 1 (2.1) 0 1 (1.0) 2 (0.5)
Capecitabin 0 3 (1.3) 3 (2.9) 6 (1.6)
Other 1 (2.1) 1 (0.4) 2 (1.9) 4 (1.0)
5-Fluorouracil 0 71 (30.5) 26 (24.8) 97 (25.1)
Alkylating agents Oxaliplatin 1 (2.1) 0 17 (16.2) 18 (4.7)
Ifosfamide 0 0 2 (1.9) 2 (0.5)
Cyclophosphamide 32 (66.7) 169 (72.5) 6 (5.7) 207 (53.6)
Cisplatin 1 (2.1) 3 (1.3) 17 (16.2) 21 (5.4)
Carboplatin 0 26 (11.2) 37 (35.2) 63 (16.3)
Other 10 (20.8) 1 (0.4) 1 (1.0) 12 (3.1)
Intercalating agents Topotecan 0 0 8 (7.6) 8 (2.1)
Mitoxantron 0 2 (0.9) 0 2 (0.5)
Irinotecan 0 0 9 (8.6) 9 (2.3)
Etoposide 4 (8.3) 1 (0.4) 18 (17.1) 23 (6.0)
Epirubicin 0 139 (59.7) 3 (2.9) 142 (36.8)
Doxorubicin 19 (39.6) 36 (15.5) 7 (6.7) 62 (16.1)
Other 0 1 (0.4) 2 (1.9) 3 (0.8)
Mitotic inhibitors Vinorelbin 0 7 (3.0) 2 (1.9) 9 (2.3)
Vinﬂunin 0 0 1 (1.0) 1 (0.3)
Vincristine 19 (39.6) 0 4 (3.8) 23 (6.0)
Vinblastine 2 (4.2) 0 0 2 (0.5)
Other 1 (2.1) 0 0 1 (0.3)
Taxane Paclitaxel 0 62 (26.6) 22 (21.0) 84 (21.8)
Docetaxel 0 88 (37.8) 7 (6.7) 95 (24.6)
Other 0 7 (3.0) 4 (3.8) 11 (2.8)
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disorders and administration site conditions
(9.9%) with the PTs mucosal inflammation
(3.4%) and fatigue (3.1%); and blood and
lymphatic system disorders (9.2%) with the
PTs neutropenia (6.5%) and leukopenia (4.5%).
During the study, eight patients (2.1%) reported
serious adverse events (SAE) (Table 10) that were
considered as potentially related to treatment of
which one patient died with an SAE with
insufficient information to define possible
relationship to treatment.
Less than one percent (0.8%) of patients had
a delay in their chemotherapy due to FN after
the first biosimilar filgrastim treatment and for
4.7% of patients, the chemotherapy in any
subsequent cycle was delayed because of
neutropenia. Reduction of the chemotherapy
dose after first biosimilar filgrastim treatment
due to FN was reported for 1% of patients and
reduction of the chemotherapy dose in any
subsequent cycle due to neutropenia was
reported for 4.7% of patients.
Patient-Reported Data
The majority of patients administered the
biosimilar filgrastim injection themselves at
both treatment visits (77.7% at first visit and
68.6% at last visit). On a scale of very difficult to
very easy, most of the self-applicators reported
that the application was easy or very easy. On a
scale of 0 (no pain) to 10 (extreme pain) most
patients perceived the pain of the biosimilar
filgrastim injection as mild (median score 1.0).
DISCUSSION
CIN is a serious and potentially life-threatening
consequence of cancer treatment mostly
observed during the first cycles of
chemotherapy [13–17]. Sepsis or severe
infections are possible complications, however,
delays and dose reductions of chemotherapy
due to neutropenia in subsequent treatment
cycles may be associated with compromised
patient outcomes [18–22]. Although the
prophylactic administration of antibiotics may
reduce the incidence of FN and mortality
related to infections [23], the guidelines of the
European Organization for Research and
Treatment of Cancer (EORTC) do not
recommend this practice [24] due to possible
emergence of antibiotic resistance. An
alternative approach is the prophylactic
treatment with G-CSF which decreases the
incidence of FN, the rate of hospitalization,
and the use of antibiotics in patients at risk [25].
The guidelines of the American Society of
Table 7 continued









Monoclonal antibodies Rituximab 28 (58.3) 0 0 28 (7.3)
Cetuximab 0 0 1 (1.0) 1 (0.3)
Bevacizumab 0 19 (8.2) 9 (8.6) 28 (7.3)
Other 2 (4.2) 27 (11.6) 0 29 (7.5)
Other cancer therapies 43 (89.6) 23 (9.9) 15 (14.3) 81 (21.0)
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Oncology (ASCO) in 2006 and those of the
National Comprehensive Cancer Network
(NCCN) in 2014 recommend the use of G-CSF
in primary prophylaxis for chemotherapy
associated with a risk of FN C20% [26]. The
2006 guidelines of EORTC updated in 2010
recommend the systematic use of G-CSF in
primary prophylaxis to prevent FN if the risk of
FN associated with the cytotoxic chemotherapy
is C20%, and in specific patients if the cytotoxic
Table 8 Leukocytes, neutrophils and C-reactive protein at visit 1, before the ﬁrst and last chemotherapy cycles, stratiﬁed by













N 43 219 95 357
Median 3.2 4.3 2.9 3.6
Before ﬁrst CT-cycle
N 42 173 85 300
Median 5.0 6.2 6.5 6.1
Before last CT-Cycle
N 29 199 72 300
Median 4.1 5.3 5.1 5.1
Neutrophils (109/L)
First visit
N 27 140 68 235
Median 1.4 1.6 1.1 1.3
Before ﬁrst CT-cycle
N 27 117 55 199
Median 2.8 3.7 3.9 3.7
Before last CT-cycle
N 16 124 51 191
Median 2.6 3.1 3.0 3.0
C-reactive protein (mg/l)
First visit
N 18 67 36 121
Median 4.5 5.2 9.7 5.2
Before ﬁrst CT-cycle
N 15 34 27 76
Median 5.3 5.1 12.9 6.8
Before last CT-cycle
N 9 47 22 78
Median 5.0 5.6 10.6 6.0
* Lab values with comments were not included in the analyses
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chemotherapy induces a risk from 10 to 20%
[24].
The use of biosimilar G-CSF (Nivestim) was
approved by the European Medicines Agency
(EMA) for all the registered indications of the
originator (Neupogen) including CIN,
agranulocytosis and neutropenia due to
infection with the HIV and mobilization of
stem cells in the autologous and allogeneic
settings, based on their comparable efficacy and
safety profile to the originator G-CSF in CIN.
Two phase I pharmacokinetic/
pharmacodynamic studies previously
confirmed the similarity between biosimilar
filgrastim and the reference product Neupogen
[27, 28] and an extensive characterization study
assessed the physiochemical similarity of
biosimilar filgrastim to Neupogen [29].
Samples were analyzed for physicochemical
properties, molecular characteristics, purity
and biological activity. They were also
compared after long-term storage to evaluate
their degradation impurity profiles. Biosimilar
filgrastim and Neupogen were shown to have
comparable physicochemical properties,
molecular characteristics, purity and biological
activity.
A phase III double-blind study demonstrated
the bioequivalence of biosimilar filgrastim and
Neupogen in patients with breast cancer treated
with doxorubicin and docetaxel in the
neoadjuvant/adjuvant or first-line metastatic
setting [30]. Among patients randomized to
receive biosimilar filgrastim (n = 184) and
Neupogen (n = 95), the mean duration of severe
neutropenia in Cycle 1 was similar for biosimilar
filgrastim (1.6 days; n = 165) and Neupogen
(1.3 days; n = 85), meeting predefined criteria
for bioequivalence. Secondary endpoints
supporting bioequivalence included mean time
to ANC recovery and incidence of FN. The
biosimilarity of these agents was further
demonstrated in a retrospective comparative
cohort study of women with early breast cancer
during (neo) adjuvant docetaxel/doxorubicin/
cyclophosphamide [31].
Table 9 AEs with at least potential relationship to study
treatment





Musculoskeletal and connective tissue
disorders
47 (12.3%)
Bone pain 29 (7.6%)
General disorders and administration site
conditions
38 (9.9%)
Mucosal inﬂammation 13 (3.4%)
Fatigue 12 (3.1%)
Blood and lymphatic system disorders 35 (9.2%)
Neutropenia 25 (6.5%)
Leukopenia 17 (4.5%)
Gastrointestinal disorders 27 (7.1%)
Nausea (3.4%) 13 (3.4%)
A relationship was assumed unless ‘no relationship’ was
recorded
Table 10 Serious adverse events with at least potential
relationship to study treatment (N = 382)
Preferred term (PT) n (%)
Death 1 (0.3%)
Drug ineffective 1 (0.3%)
General physical health deterioration 1 (0.3%)
Pleural effusion 1 (0.3%)
Pulmonary embolism 1 (0.3%)
Neutropenia 1 (0.3%)
Atrial ﬂutter 1 (0.3%)
Anal abscess 1 (0.3%)
A relationship was assumed unless ‘no relationship’ was
recorded
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Through analysis of real-world day-to-day
use, the results of the VENICE study extend the
results of a recent review of available data,
which concluded the safety of biosimilar
filgrastim is similar to Neupogen [32]. In this
study, the majority of the patients (64%)
received biosimilar filgrastim as primary
prophylaxis and 36% as secondary
prophylaxis. Because most of the patients were
female with breast cancer, there was no widely
used primary prophylaxis. Nevertheless, for
some patients with breast cancer who received
combination chemotherapy associated with a
FN risk[20% [i.e., TAC (docetaxel, doxorubicin,
cyclophosphamide) Dose-dense AC/T
(doxorubicin, cyclophosphamide, paclitaxel)] a
primary prophylaxis with G-CSF is
recommended [13]. Additionally, age is a risk
factor [13] and justifies the prophylactic
treatment of G-CSF. The median age was 61
and 39% of the patients were[65 years old.
The limitations of this study include that it is
non-interventional, observational and lacks a
blinded control. Additionally, a weakness is the
lack of data captured, specifically regarding the
chemotherapy regimens and severity of FN.
The use of biosimilar filgrastim according to
the label in the VENICE observational study was
effective and well-tolerated in both the primary
and secondary prophylactic setting in patients
undergoing CT for solid tumors and
hematological malignancies. The rate
neutropenia observed (Table 10) of 0.3% is
lower than the rate of neutropenia in the
baseline characteristics (2.6%). Reduction of CT
dose or delayed start of next CT cycle due to
neutropenia were observed in approximately 1%
of the patients after first biosimilar filgrastim
treatment. No hospitalizations for FN occurred
during the study; 2% of the patients were
hospitalized because of infections. At least one
AE with at least potential relationship to
treatment was reported by 30% of patients
during the study. The most frequently reported
AEs with at least potential relationship to
treatment were in the SOC ‘Musculoskeletal
and connective tissue disorders’ (12.3%) with
the PT bone pain (7.6%).
Most patients administered the biosimilar
filgrastim injection themselves at both
treatment visits and the majority of the
self-administrators reported that the
application was easy or very easy. The
perception of pain during the biosimilar
filgrastim injection was mild for the majority
of patients.
CONCLUSION
The VENICE observational study was designed
to evaluate the use of Nivestim according to
label-mandated posology for the administration
of G-CSF and thereby provided additional real
world data on supportive care for cancer
patients. Biosimilar filgrastim was effective and
well-tolerated in both the primary and
secondary prophylactic settings in patients
undergoing CT for solid tumours and
haematological malignancies.
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